Madrigal Pharmaceuticals Inc
NASDAQ:MDGL

Watchlist Manager
Madrigal Pharmaceuticals Inc Logo
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Watchlist
Price: 338.54 USD -1.14%
Market Cap: 7.5B USD

Net Margin
Madrigal Pharmaceuticals Inc

-258.6%
Current
-340%
Average
-7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-258.6%
=
Net Income
-465.9m
/
Revenue
180.1m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
7.3B USD
-259%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
372.5B USD
8%
US
Amgen Inc
NASDAQ:AMGN
168.5B USD
12%
US
Gilead Sciences Inc
NASDAQ:GILD
133.4B USD
2%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
130.3B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
121.2B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.5B USD
31%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
33.8B EUR
38%

Madrigal Pharmaceuticals Inc
Glance View

Economic Moat
None
Market Cap
7.4B USD
Industry
Biotechnology

In the competitive and complex landscape of pharmaceuticals, Madrigal Pharmaceuticals Inc. has carved a niche for itself by focusing on the development of innovative therapies for metabolic and liver diseases. Founded with the visionary zeal to address unmet medical needs, Madrigal's journey is grounded in its dedication to advancing science and transforming patient care. The company's primary research and development efforts center around addressing non-alcoholic steatohepatitis (NASH), a significant liver condition that lacks approved treatments. With a keen eye on scientific innovation, Madrigal invests heavily in creating solutions for conditions that are not only challenging but also growing in prevalence, thus embodying the dual mission of driving better health outcomes and capturing market opportunities. Madrigal's business model is largely reliant on the successful progression of its lead candidate, resmetirom, through clinical trials and regulatory approval processes. This strategy, typical in the pharmaceutical arena, involves rigorous stages of testing to ensure efficacy and safety, aiming to bring the drug to market where it can address the substantial need. Revenue generation for Madrigal is intrinsically linked to licensing agreements, strategic partnerships, and eventual drug sales post-approval. This approach necessitates significant initial investment and patience, with the expectation of substantial returns contingent upon successful product commercialization. Through this focus, Madrigal advances towards not only improving the therapeutic landscape for liver diseases but also carving out a significant presence in the biotech market.

MDGL Intrinsic Value
465.74 USD
Undervaluation 27%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-258.6%
=
Net Income
-465.9m
/
Revenue
180.1m
What is the Net Margin of Madrigal Pharmaceuticals Inc?

Based on Madrigal Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -258.6%.

Back to Top